Ypsomed Holding AG · SIX:YPSN

Ypsomed — Corporate Update (September 2006)

14 slides from Ypsomed's corporate update, Sep 14, 2006

  1. Slide 1: Information on Ad-hoc Announcement

    Information on Ad-hoc Announcement Solothurn, 14th September 2006

  2. Slide 2: Important Notice

    Important Notice The information contained in this document has not been independently verified and no representation or warranty, express or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein.

  3. Slide 3: Agenda

    Agenda ƒ Ad-hoc Announcement – Sales and profit below expectations ƒ Richard Fritschi appointed as new CEO ƒ Questions and Answers ƒ Additional Information on company and products 3

  4. Slide 4: Ad-hoc Announcement

    Ad-hoc Announcement ƒ The production problems and interruption related to the OptiClik® reusable module have a negative effect on sales and EBIT in the first half year 2006/07. Sanofi-Aventis has reduced orders and order forecasts for 2006/07 for insulin pens. The main reason given by Sanofi-Aventis

  5. Slide 5: Agenda

    Agenda ƒ Ad-hoc Announcement – Sales and profit below expectations ƒ Richard Fritschi appointed as new CEO ƒ Questions and Answers ƒ Additional Information on company and products 5

  6. Slide 6: Richard Fritschi appointed new CEO

    Richard Fritschi appointed new CEO ƒ 15 years of professional experience in medtech (Zimmer, Centerpulse and SulzerMedica) ƒ Proven international leadership and M&A track record, i.e. Zimmer take-over of Centerpulse, several large acquisitions and turnaround situation with Sulzer Medica ƒ Internatio

  7. Slide 7: Richard Fritschi – Professional Career

    Richard Fritschi – Professional Career ƒ 2003-2006 Zimmer, President Europa & Australasia (CHF 1.3 billion in sales and 2‘000 employees) ƒ 2001-2003 SulzerMedica/Centerpulse, President Europe, Asia & Latin America ƒ 1998-2000 Sulzer Orthopedics, General Manager Global Sales (CHF 800 million in sales

  8. Slide 8: Agenda

    Agenda ƒ Ad-hoc Announcement – Sales and profit below expectations ƒ Richard Fritschi appointed as new CEO ƒ Questions and Answers ƒ Additional Information on company and products 8

  9. Slide 9: Questions & Answers

    Questions & Answers YPS©MED SELFCARE SOLUTIONS aby

  10. Slide 10: Agenda

    Agenda ƒ Ad-hoc Announcement – Sales and profit below expectations ƒ Richard Fritschi appointed as new CEO ƒ Questions and Answers ƒ Additional Information on company and products 10

  11. Slide 11: Ypsomed's Growth Strategy

    Ypsomed‘s Growth Strategy ƒ Ypsomed is the technology leader and number one independent manufacturer of injection systems worldwide. ƒ Ypsomed’s strategy is focused to maintain and expand its position in the future. ƒ In order to achieve this objective, Ypsomed will… ƒ Improve production capacity in

  12. Slide 12: Overview of Products and Applications

    Overview of Products and Applications Ypsomed’s activities are organized in three business sectors: Self Injection Devices Pen Needles Diabetes Care (OEM Business) ƒ Development and ƒ Development and ƒ Local access to manufacturing of custom- manufacturing of pen customers and opinion made self-inje

  13. Slide 13: Overview of Pharma Partnerships

    Overview of Pharma Partnerships Insulin hGH interferon & EPO 13

  14. Slide 14: Overview of Pharma Partnerships

    Overview of Pharma Partnerships r-hFSH r-PTH Symlin ... and other partners 14

Ypsomed Holding — Corporate Update (September 2006) on 6ix